- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT04363632
Prospective Analysis of Morbi-mortality of Patients With Cancers in Active Phase of Treatment Suspected or Diagnosed of a SARS-CoV-2 Infection (ONCOVID-19)
Studieöversikt
Status
Betingelser
Studietyp
Inskrivning (Faktisk)
Kontakter och platser
Studieorter
-
-
-
Bordeaux, Frankrike
- Institut Bergonié
-
Caen, Frankrike, 14076
- Centre Francois Baclesse
-
Chambéry, Frankrike, 73011
- Centre Hospitalier Metropole Savoie
-
Clermont-Ferrand, Frankrike, 63011
- Centre Jean Perrin
-
Dijon, Frankrike, 21079
- Centre Georges François Leclerc
-
Lille, Frankrike, 59020
- Centre Oscar Lambret
-
Lyon, Frankrike, 69373
- Centre Léon Bérard
-
Metz-Tessy, Frankrike, 74370
- CH Annecy-Genevois
-
Montpellier, Frankrike, 34298
- Institut de Cancérologie de Montpellier
-
Montélimar, Frankrike, 26216
- Groupement Hospitalier Porte de Provence
-
Nice, Frankrike
- Centre Antoine Lacassagne
-
Pierre-Bénite, Frankrike, 69495
- Centre Hospitalier Lyon-Sud
-
Reims, Frankrike, 51726
- Institut Jean Godinot
-
Rouen, Frankrike, 76038
- Centre Henri Becquerel
-
Saint-Herblain, Frankrike, 44805
- Institut de Cancérologie de l'Ouest
-
Strasbourg, Frankrike, 67033
- Institut de cancerologie Strasbourg Europe (ICANS)
-
Toulouse, Frankrike, 31059
- Institut Universitaire du Cancer de Toulouse - IUCT Oncopole
-
Valence, Frankrike
- Ch Valence
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
- Barn
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Beskrivning
Inclusion Criteria:
I1. Confirmed diagnosis of any type of solid or hematologic tumor;
I2. Ongoing anticancer treatment (cytotoxic, targeted therapy, immunotherapy or loco regional procedure, including radiotherapy, surgery or interventional radiology procedure) at the time of inclusion or within the last 3 months prior to inclusion (last treatment administration or last loco regional procedure) ;
I3. Patient with suspicion of COVID-19 (clinical symptoms of COVID-19 including fever (>38°C) and/or respiratory tract symptoms), either confirmed or not.
Note 1: Patients must have underwent diagnostic procedures: diagnostic test (positive or negative) and/or chest imaging. Note 2: Patients will be eligible regardless of the presence of a neutropenia (either febrile or not) ;
I4. Patient and/or family did not decline data collection after complete information.
Studieplan
Hur är studien utformad?
Designdetaljer
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Mortality of cancer patients under active anticancer treatment
Tidsram: 28 days after the date of the diagnostic procedure
|
Mortality rate, defined as the proportion of patients who are dead 28 days after the date of the diagnostic procedure for the 2 cohorts of patients (positive and negative).
|
28 days after the date of the diagnostic procedure
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Overall survival
Tidsram: 6 months (i.e. at the the time of last patient last visit)
|
Overall survival will be defined as the time from the date of the first diagnostic procedure (either diagnostic test or chest imaging) to the date of death due to any cause.
|
6 months (i.e. at the the time of last patient last visit)
|
Hospitalizations
Tidsram: 28 days after the date of the diagnostic procedure
|
The duration of hospitalization (from the date of hospitalization to the date of definitive discharge for live patients)
|
28 days after the date of the diagnostic procedure
|
Death
Tidsram: 6 months (i.e. at the the time of last patient last visit)
|
Cause of death, related or not to the COVID-19
|
6 months (i.e. at the the time of last patient last visit)
|
Complications
Tidsram: 28 days after the date of the diagnostic procedure
|
Associated complications described by their type
|
28 days after the date of the diagnostic procedure
|
Hospitalizations
Tidsram: 28 days after the date of the diagnostic procedure
|
proportion of hospitalizations
|
28 days after the date of the diagnostic procedure
|
Patients' characteristics
Tidsram: At the date of the diagnostic procedure
|
To describe accurately patients' characteristics in terms of demographics
|
At the date of the diagnostic procedure
|
Patients' characteristics
Tidsram: At the date of the diagnostic procedure
|
To describe accurately patients' characteristics in type of tumor
|
At the date of the diagnostic procedure
|
Patients' characteristics
Tidsram: At the date of the diagnostic procedure
|
To describe accurately patients' characteristics in type of anticancer treatment,
|
At the date of the diagnostic procedure
|
Patients' characteristics
Tidsram: At the date of the diagnostic procedure
|
To describe accurately patients' characteristics in terms of comorbidities
|
At the date of the diagnostic procedure
|
Samarbetspartners och utredare
Sponsor
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- ET20-069
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .